CROSSJECT news, videos and press releases - Page 2
For more news please use our advanced search feature.
CROSSJECT - More news...
CROSSJECT - More news...
- CROSSJECT reports financial results for 2024
- CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
- CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones
- Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
- COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE
- Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System
- Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
- Crossject to report first-half 2024 financial results and host webcast on September 23, 2024
- Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
- Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
- Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
- Crossject announces highly successful closing of its €8 million rights offering
- Crossject trading on Euronext to resume as usual on Wednesday April 3
- Crossject advances in its U.S. Strategy and reports Financial Results for 2023
- Crossject gender equality score reaches 96/100 in 2024
- Crossject obtains a financing up to €12 million, in two tranches
- Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
- Crossject to present at Biotech Showcase on January 9 at 16:30 PT
- Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
- Crossject signs ZEPIZURE® commercialization agreement for northern Europe
- Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
- Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
- Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
- Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition
- CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
- CROSSJECT: Agreement with BARDA on ZENEO® Midazolam
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
- Crossject : Information relative au nombre de droits de vote et d'actions composant le capital social
- CROSSJECT : Financial calendar 2018
